A limitation is inability to compare serum NfL levels in estriol‐treated MS subjects with those on highly effective approved DMTs, since NfL assays here11, 12 differed slightly in methodology from that recently used to establish reference values across clinical trials.24 The gene discussed is NEFL; the disease is myeloid sarcoma.